Psychiatry's Struggle: Progress Stalls, Trust Wanes

Available interventions often lead to iatrogenic, or treatment-induced, problems for patients.

Andrew Scull stated, "What we have available to us are symptomatic treatments not cures. We don't have a psychiatric penicillin for any of the conditions we're gonna be talking about." This fundamental lack of a 'psychiatric penicillin' underscores the field's ongoing challenge in addressing core mental health conditions.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) introduced a 'tick-the-boxes' approach to diagnosis in 1980, aiming to improve reliability among practitioners. While this method enhanced agreement between doctors, the fundamental validity of these diagnoses remains questionable.

Labels such as 'schizophrenia' or 'depression' often function more as social constructs than reflections of underlying biological truths. Critics contend that these symptom-based categories can misguide both research efforts and individual treatment paths, hindering genuine understanding of mental illness.

Andrew Scull explained, "Reliability means you and I faced with the same sets of facts reach the same conclusion but that conclusion may or may not reflect the underlying reality of things right?"

Former NIMH director Thomas Insel admitted limited success after 13 years at the helm.

The strategic shift toward viewing mental illness strictly as 'brain disease' did not yield the anticipated cures. This focus on genetics and neuroscience, while promising in theory, ultimately overpromised on clinical results, leading to a stagnation in patient care.

Andrew Scull highlighted this failure, stating, "And after spending 20 billion dollars, the lot of the mentally ill has improved not one bit right?"

Historically, the field neglected biological factors, a shortcoming that has now reversed to a modern neglect of psychological models. The critical need to integrate both levels of understanding, encompassing both brain and mind, remains largely unfulfilled, perpetuating an incomplete view of mental health.

Andrew Scull paraphrased this observation, noting, "When I entered psychiatry, it was brainless psychiatry, leaving it mindless psychiatry."

On average, people with serious mental illness die 15 to 25 years earlier than the general population, a gap that is actively growing rather than diminishing. Patients often find themselves trapped in a cycle of brief hospitalizations, followed by periods of homelessness and incarceration, highlighting a profound societal and systemic failure.

Andrew Scull underscored this grave reality: "So if you, a person with serious mental illness, you will die on average fifteen to twenty-five years before the rest of us. That gap has been growing rather than diminishing."

His ambidextrous skill allowed him to perform 20-30 lobotomies in a single afternoon, demonstrating his aggressive approach to the practice. Lobotomies continued as a mainstream treatment until the 1970s, when they were gradually replaced by the advent of antipsychotic medications.

Andrew Scull quotes Freeman, who boldly stated, "You know I could teach any damn fool to perform a lobotomy in twenty minutes even a psychiatrist."

GPI presented with both severe neurological failure and bizarre psychiatric symptoms, directly linking a specific mental condition to a known physical cause. This groundbreaking finding mistakenly led many to believe that all forms of mental illness would eventually be found to have similar infectious origins.

Despite wildly exaggerated claims of its efficacy, the treatment was widely adopted and remained standard practice until the discovery of penicillin. This intervention, though lauded at the time, subjected patients to severe and often life-threatening conditions.

Andrew Scull described the process: "And they brought him to him, and he extracted the malarial blood and injected it into a series of patients with GPI, with general paralysis of the insane, and claimed it cured them."

His radical approach involved mass surgeries where he removed healthy body parts, including stomachs, colons, and teeth, in an attempt to eliminate supposed bacterial infections. Many patients were left disabled or dead due to these extreme procedures, yet the practice was surprisingly lauded by the press and medical establishment for a time.

Andrew Scull quoted Cotton's rationale: "So what are we gonna do about this Well we can perhaps locate the bacterial infection and then we can Get rid of it We can engage in what he calls surgical bacteriology"

Manfred Sakel introduced insulin coma therapy, claiming it cured 80% of schizophrenics, a percentage that frequently appeared in exaggerated claims for various treatments. This brutal treatment induced comas, often leading to seizures and significant brain damage in patients. John Nash, the Nobel laureate, was among the many individuals subjected to this dangerous and ultimately failed intervention, which caused more harm than good.

Andrew Scull noted Sakel's claim: "He claimed that this Insulin Coma Treatment cured eighty percent of his -- eighty percent tends to come up again and again in these treatments as a sort of percentage that you cure."

Dr. Ladislas Meduna wrongly believed that schizophrenia and epilepsy were mutually exclusive, leading to the idea that inducing an epileptic seizure could 'drive out' schizophrenia. Early attempts with camphor and Metrazol caused violent seizures and frequent bone fractures, necessitating a search for less brutal methods.

Italian psychiatrists Cerletti and Bini observed pig slaughterhouse practices to refine electroshock techniques, transitioning to direct electrical stimulation. Initially, ECT was often used punitively to control patient behavior rather than as a therapeutic intervention, reflecting the primitive understanding of mental illness.

Andrew Scull describes Meduna's flawed logic: "If you had epilepsy, you didn't have schizophrenia. If you had schizophrenia, you couldn't have epilepsy... So then, the logical next step was, 'Well, if we could create an artificial epileptic seizure, maybe we would drive out the schizophrenia.'"

The modernization of electroconvulsive therapy (ECT) successfully eliminated physical trauma, but significant ethical controversies persist. The introduction of muscle relaxants largely ended the problem of fractures caused by seizures, making the procedure physically safer. However, this also necessitated anesthesiology support due to the respiratory risks associated with muscle paralysis.

Despite these advancements, critics continue to argue that ECT causes severe memory loss and potential brain damage. It remains a controversial last-resort intervention, typically reserved for treatment-resistant, suicidal depression, highlighting ongoing debates about its long-term effects and appropriateness.

Andrew Scull explained the critical improvement: "What changed ECT a bit, quite a bit actually, was giving muscle relaxants so that people didn't thrash about, and the fractures were largely a thing of the past."

This mistrust results in aborted clinical trials and the loss of critical knowledge that could otherwise advance treatment. Compounding this issue are funding cuts and training gaps for new scientists, further hindering research and development.

Scientific breakthroughs are inherently rare, often requiring years of trial and error through many 'blind alleys' before success. Hyperbolic science journalism, by hyping minor findings, further undermines long-term credibility and exacerbates public skepticism.

Andrew Scull warned about the severe consequences of this erosion: "After four years of this, first of all, the degree of mistrust will have grown exponentially, and once trust is lost, it's very hard to recover. Secondly, the science itself is being destroyed."

Genome-wide association studies have failed to identify simple Mendelian genes that would definitively explain conditions like schizophrenia or bipolar disorder. Instead, psychiatric genetics increasingly suggests a massive overlap between disorders such as autism, bipolar disorder, and schizophrenia, challenging traditional classifications.

Leading psychiatrists now speculate that these disorders may exist on a continuum rather than as clearly defined, separate entities. This paradigm shift, however, threatens public trust, as diagnostic boundaries become increasingly blurred, making it harder for the public to understand and accept psychiatric diagnoses.

Andrew Scull noted the potential impact: "If psychiatry has to say in ten years... that there's no such thing as schizophrenia, there's no such thing as bipolar disorder, that will tend, I suspect, to have pretty bad effects on people's trust in psychiatry."

Cognitive Behavioral Therapy (CBT) exemplifies this approach by prioritizing quick, measurable results. This methodology focuses on breaking bad habits and developing coping techniques rather than exploring a patient's underlying history, offering a more reproducible and testable alternative to traditional psychoanalysis.

Andrew Scull described their approach: "The clinical psychologists go, 'We're gonna treat the symptoms of what are troubling people. We're gonna treat the symptoms, and we're gonna develop techniques that allow people to cope with those symptoms and eliminate them.'"

As a disillusioned psychoanalyst, he pivoted to cognitive therapy, where his observations highlighted the profound lack of consensus among psychiatrists regarding patient diagnoses. His critical insights were instrumental in the development of DSM-III, which aimed to improve diagnostic reliability.

Andrew Scull acknowledged his significance: "Aaron Beck is a remarkable figure because he was also one of the first in the 1960s to look at psychiatric diagnosis and show how unreliable it was, how-- how difficult it was to get psychiatrists to agree on what was wrong."

Renamed a 'major tranquilizer' and later an 'antipsychotic,' chlorpromazine fundamentally shifted mental hospital management toward chemical sedation, profoundly impacting patient care and institutional practices.

Andrew Scull quotes Laborit's assessment: "He said, 'This like, this works like a chemical lobotomy. These people don't care anymore about their surgery.'"

SmithKline & French transformed from a small company into a major player largely due to the success of Thorazine. They employed compelling visual aids, such as moving pictures of agitated patients becoming calm after medication, to sway state politicians.

This strategy led to widespread adoption of chemical treatments and spurred the emergence of numerous copycat drugs, initiating the boom in minor tranquilizers. These marketing efforts fundamentally shaped the landscape of psychiatric care and medication usage.

Andrew Scull described the marketing approach: "The companies wake up, they sell it to the politicians. They go to the state legislatures. They have moving pictures of an agitated patient who turns calm, you know."

Patients developed incurable jerky movements and facial twitching, often mistaken for symptoms of mental illness itself. If someone exhibiting these symptoms walked down the street, they would be perceived as mentally ill, when in reality, they were suffering from the side effects of their medication.

The condition is called 'tardive' because it develops late after treatment initiation, and 'dyskinesia' refers to the uncontrolled body movements. It was only after George Crane's paper in Science finally brought the issue to light that the medical community began to acknowledge this devastating consequence of psychiatric drugs.

Andrew Scull explained: "Tardive because it's late developing... and dyskinesia because what involves is jerky uncontrolled movements of the body... If somebody like that is walking down the street towards you, you will think there's a mentally ill person... what you're seeing is the iatrogenic effects of the drugs they're on."

Modern antipsychotics do not outperform first-generation drugs in efficacy, as revealed by the 2005 CATIE Study funded by NIMH. This extensive research found no clinical superiority for newer, often ten times more expensive, second-generation medications compared to older, cheaper versions. The study highlighted that 67% to 82% of patients discontinued the trial due to either side effects or a lack of efficacy, indicating persistent challenges in treatment. Andrew Scull plainly stated, "Are the new drugs more efficacious than the old drug? No."

Common adverse effects include metabolic syndrome, diabetes, and significant weight gain, which can exacerbate existing health issues or create new ones. The absence of reliable biological markers makes it impossible to predict individual patient responses to specific medications.

As a result, psychiatric treatment often remains a process of trial and error for clinicians, requiring careful monitoring and adjustment. Patients must weigh the potential relief from psychiatric symptoms against the various dangers that may or may not arise from the drugs, making each treatment decision highly individualized and precarious.

Andrew Scull summarized this dilemma: "It's one of these cost-benefit analyses, right? You're getting some relief from your psychiatric symptoms, but you're courting these other dangers that may or may not arise."

While SSRIs show statistical significance in studies, they often lack substantial clinical benefits for depression, with much of their perceived effect attributed to the placebo effect. For most patients, antidepressants are only marginally better than a placebo, suggesting that expectation and belief play a significant role in outcomes. Many antidepressants are prescribed by primary care doctors rather than specialists, potentially leading to less specialized oversight and management.

Withdrawal from SSRIs is frequently described by patients as 'hell on wheels,' indicating severe and distressing discontinuation symptoms. This underscores the need for careful consideration of their efficacy and potential challenges in long-term use, especially given the strong influence of the placebo effect.

Andrew Scull observed, "For most patients, antidepressants are marginally better than placebo, but a lot of the effect is the placebo effect."

Currently, academic funding often restricts the study of crucial social issues like homelessness, despite their profound impact on mental well-being. Mental illness remains a profoundly lonely experience for sufferers, highlighting the need for comprehensive support systems beyond medication.

The future of the field depends on a fundamental shift in professional mentality, one that embraces the psychosocial dimensions of mental illness and allows psychiatrists to build careers in these vital areas. This change would foster a more holistic and compassionate approach to mental health care.

Andrew Scull emphasized, "We need to spend some time on the psychosocial dimensions of mental illness and to allow psychiatrists to build careers in those fields."